Price movement over the last 24 hours
Adecoagro SA vs Enveric Biosciences Inc — how do they compare? Adecoagro SA trades at $10.19 (market cap $1.39B), while Enveric Biosciences Inc trades at $1.37 (market cap $5.84M). The key difference: Adecoagro SA is far larger — about 238× Enveric Biosciences Inc's market cap, and Adecoagro SA pays a 3.08% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| AGRO | ENVB | |
|---|---|---|
Market Cap | $1.39B | $5.84M |
Sector | Technology | Health |
52-Week High | $15.25 | $17.40 |
52-Week Low | $7.13 | $1.28 |
Enterprise Value | $3.42B | $932.52K |
Dividend Yield | 3.08% | — |
Signals from Pluang's Aura AI — not financial advice
AGRO trades at $9.48, down 1.66% today, with a bearish technical signal despite neutral oscillators. The company reported mixed quarterly results, missing Q1 2026 EPS estimates but showing strong adjusted EBITDA growth. Valuation metrics appear attractive with P/S of 0.71 and P/B of 0.78, though profitability remains weak with a 0.91% net margin. Recent news highlights innovation in agriculture operations and a declared $0.12 dividend for H1 2026.
The stock offers value appeal with below-market multiples and analyst consensus target of $12.75 implying 34% upside. However, inconsistent earnings performance and negative net income in 2025 pose execution risks. The bearish technical trend and competitive pressures in sustainable agriculture require careful monitoring for potential investors.
ENVB trades at $1.48, up 2.07% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, with negative ROE and ROA, yet consistently beat earnings expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies.
The outlook is mixed: strong analyst support (75% buy ratings) and positive clinical updates contrast with deep losses and bearish technicals. Key risks include clinical trial outcomes and cash burn, while institutional financing provides near-term stability. Upside depends on successful drug development.
Trailing returns across standard periods
Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.
Read more on AGRO →Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →